| human | Q5 |
| P496 | ORCID iD | 0000-0002-1575-1005 |
| P1053 | ResearcherID | O-2251-2014 |
| P1153 | Scopus author ID | 7004218890 |
| P734 | family name | Encabo | Q37482159 |
| Encabo | Q37482159 | ||
| Encabo | Q37482159 | ||
| P735 | given name | Gloria | Q734575 |
| Gloria | Q734575 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q53161715 | 33% radius evaluation to assess bone mineral density in prostate cancer patients. |
| Q42455896 | Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. |
| Q83116563 | Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression |
| Q71083174 | Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer |
| Q59274557 | Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions |
| Q39519200 | Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostatic specific antigen. |
| Q73407574 | Measurement of free PSA in the diagnosis and staging of prostate cancer |
| Q34043841 | Measuring health-related quality of life in men with osteoporosis or osteoporotic fracture |
| Q79329813 | Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment |
| Q60708224 | Postprandial serum cholylglycine in the detection of hepatotoxicity induced by antituberculous agents |
| Q33805608 | Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. |
| Q43418028 | Prediction of frailty fractures or prediction of densitometric osteoporosis. That is the question! |
| Q80027418 | Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer |
| Q83972883 | Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass |
| Q77880101 | The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer |
| Q84162943 | [Differences in the predictive values of the FRAX™ tool between the Spanish and United Kingdom population and considerations about the intervention threshold] |
| Q50480337 | [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population]. |
| Q82145381 | [New evidence on the discriminant and predictive capacity of the FRAX(®) tool in a Spanish female population] |
| Q84796971 | [Precautions required on using the predictive thresholds of the FRAX® tool to decide the need for an axial bone density scan in the Spanish population] |
Search more.